

Session Title: #52: Future Treatment Approaches toward Colorectal Cancer: New Therapeutic Pathways, New Targets

Session Type: Education Session

Date: Friday, June 4

Location: E Hall D1

Time: 2:45 PM - 4:00 PM

- Membrane receptors as targets for therapeutic approaches in colorectal cancer

Josep Taberero, MD

- Intracellular components of signal transduction pathways as therapeutic targets in colorectal cancer

Wells A. Messersmith, MD

- Small and large-molecule angiogenesis inhibitors - excitement and disappointments

Scott Kopetz, MD

Session Title: #48: The Expanding Role of Antibody-based Therapy in Children, Adolescents, and Young Adults with Cancer

Session Type: Education Session

Date: Saturday, June 5

Location: S504

Time: 8:00 AM - 9:15 AM

- Progress in treatment of high-risk neuroblastoma with immunotherapy

Alice L. Yu, MD, PhD

- Update on Immunotherapy Strategies in the Treatment of Lymphomas in children, adolescents and young adults

Mitchell S. Cairo, MD

- The efficacy of epitope-specific IGFR1 antibodies in therapy of pediatric, adolescent and young adult solid tumors

Douglas Yee, MD

Session Title: #71: Melanoma Immunotherapy: Current Status, Future Opportunities

Session Type: Education Session

Date: Saturday, June 5

Location: S406 (Vista Room)

Time: 8:00 AM - 9:15 AM

- Adoptive T Cell transfer

Patrick Hwu, MD

- Checkpoint blockade

Jedd D. Wolchok, MD, PhD

- Melanoma vaccines

Craig L. Slingluff, MD

Session Title: #175: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

Session Type: Poster Discussion Session

Date: Saturday, June 5

Location: E450a

Time: 8:00 AM - 12:00 PM

- Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

Razelle Kurzrock, MD

- Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

Lesley Seymour, MD, PhD

1 #2515-Phase I trials of novel molecularly targeted therapies: Should we pay more attention to toxicities occurring after cycle 1?

Sophie Postel-Vinay

2 #2516-Should patients with malignant intracranial space occupying lesions (M-ICSOLs) be excluded from phase I trials? The Royal Marsden Hospital Drug Development Unit experience.

Dionysios Papadatos-Pastos, MD, MRCP

3 #2517-An international pooled analysis identifying predictive factors associated with toxicities in phase I trials (Delphi).

Carlos Alberto Gomez-Roca

4 #2518-Multi-institutional prognostic factor analysis of patients (pts) enrolled in phase I (Ph I) oncology trials: Can pts selection be improved?

5 #2519-Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single-center experience.

Salma M. Alam

6 #2520-VEGF pathway therapy: Resampling positive phase III data to assess phase II trial designs and endpoints.

Manish Sharma

- Discussion

David J Stewart

7 #2521-The trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with malignant ascites: Immunomonitoring results of a pivotal phase II/III study (pooled population).

Michael Jäger

8 #2522-Phase I PK/PD study of RO5083945 (GA201), the first glycoengineered anti EGFR monoclonal antibody (mAb) with optimized antibody dependent cellular cytotoxicity (ADCC).

Ben Markman

9 #2523-Radioimmunotherapy (RIT) with 131I-L19SIP in solid cancers (SC) and lymphoproliferative diseases: Final results of the first human trial.

Gianluca Del Conte

10 #2524-First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2.

Lee S. Rosen

11 #2525-Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors.

Amita Patnaik

- Discussion

Ravi Salgia, MD, PhD

12 #2526-Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist, CS-7017, in patients with advanced malignancies.

Michael J. Pishvaian

13 #2527-Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): A California Cancer Consortium trial.

Timothy W. Synold, PharmD

14 #2528-AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies.

Thomas A. Samuel, MD

15 #2529-A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors.

Jonathan Wade Goldman

16 #2530-Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors.

Craig Peter Carden

17 #2531-Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors.

T.R. Jeffry Evans

- Discussion

Lesley Seymour, MD, PhD

18 #2532-Interim results of a phase I trial of intraventricular rituximab plus methotrexate in recurrent CNS lymphoma: Macrophage polarization and acquired resistance to therapy.

James L. Rubenstein

19 #2533-A phase I study of celecoxib (C) and patupilone (EPO906) in patients (pts) with metastatic colorectal cancer (mCRC).

Syma Iqbal

20 #2534-A phase I study of the mTOR inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel (nab-P).

Maysa M. Abu-Khalaf, MD

21 #2535-A phase I study of gemcitabine, capecitabine, and vandetanib in patients with advanced solid tumors with an expanded cohort in biliary and pancreatic malignancies.

Sujatha Nallapareddy

22 #2536-A phase I study of aflibercept, pemetrexed (P), and cisplatin (C) in patients with advanced solid tumors.

Carol A. Townsley

23 #2537-Targeted cancer therapies: FDA approval overview.

Patricia Cortazar

24 #2538-Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors.

John S. Kauh, MD

- Discussion

Razelle Kurzrock, MD

Session Title: #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Session Type: Special Session

Date: Saturday, June 5

Location: N Hall B1

Time: 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Daniel D. Von Hoff, MD

Session Title: #242: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

Session Type: Poster Discussion Session

Date: Saturday, June 5

Location: E354b

Time: 12:00 PM - 1:00 PM

- Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

Razelle Kurzrock, MD

- Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

Lesley Seymour, MD, PhD

1 #2515-Phase I trials of novel molecularly targeted therapies: Should we pay more attention to toxicities occurring after cycle 1?

Sophie Postel-Vinay

2 #2516-Should patients with malignant intracranial space occupying lesions (M-ICSOLs) be excluded from phase I trials? The Royal Marsden Hospital Drug Development Unit experience.

Dionysios Papadatos-Pastos, MD, MRCP

3 #2517-An international pooled analysis identifying predictive factors associated with toxicities in phase I trials (Delphi).

Carlos Alberto Gomez-Roca

4 #2518-Multi-institutional prognostic factor analysis of patients (pts) enrolled in phase I (Ph I) oncology trials: Can pts selection be improved?

David Olmos

5 #2519-Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single-center experience.

Salma M. Alam

6 #2520-VEGF pathway therapy: Resampling positive phase III data to assess phase II trial designs and endpoints.

Manish Sharma

- Discussion

David J Stewart

7 #2521-The trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with malignant ascites: Immunomonitoring results of a pivotal phase II/III study (pooled population).

Michael Jäger

8 #2522-Phase I PK/PD study of RO5083945 (GA201), the first glycoengineered anti EGFR monoclonal antibody (mAb) with optimized antibody dependent cellular cytotoxicity (ADCC).

Ben Markman

9 #2523-Radioimmunotherapy (RIT) with 131I-L19SIP in solid cancers (SC) and lymphoproliferative diseases: Final results of the first human trial.

Gianluca Del Conte

10 #2524-First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiotensin 2.

Lee S. Rosen

11 #2525-Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors.

Amita Patnaik

- Discussion

Ravi Salgia, MD, PhD

12 #2526-Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist, CS-7017, in patients with advanced malignancies.

Michael J. Pishvaian

13 #2527-Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): A California Cancer Consortium trial.

Timothy W. Synold, PharmD

14 #2528-AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies.

Thomas A. Samuel, MD

15 #2529-A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors.

Jonathan Wade Goldman

16 #2530-Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors.

Craig Peter Carden

17 #2531-Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors.

T.R. Jeffry Evans

- Discussion

Lesley Seymour, MD, PhD

18 #2532-Interim results of a phase I trial of intraventricular rituximab plus methotrexate in recurrent CNS lymphoma: Macrophage polarization and acquired resistance to therapy.

James L. Rubenstein

19 #2533-A phase I study of celecoxib (C) and patupilone (EPO906) in patients (pts) with metastatic colorectal cancer (mCRC).

Syma Iqbal

20 #2534-A phase I study of the mTOR inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel (nab-P).

Maysa M. Abu-Khalaf, MD

21 #2535-A phase I study of gemcitabine, capecitabine, and vandetanib in patients with advanced solid tumors with an expanded cohort in biliary and pancreatic malignancies.

Sujatha Nallapareddy

22 #2536-A phase I study of aflibercept, pemetrexed (P), and cisplatin (C) in patients with advanced solid tumors.

Carol A. Townsley

23 #2537-Targeted cancer therapies: FDA approval overview.

Patricia Cortazar

24 #2538-Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors.

John S. Kauh, MD

- Discussion

Razelle Kurzrock, MD

Session Title: #149: Developmental Therapeutics - Experimental Therapeutics

Session Type: Oral Abstract Session

Date: Saturday, June 5

Location: E Hall D2

Time: 1:00 PM - 4:00 PM

- Developmental Therapeutics - Experimental Therapeutics

Richard H. Wilson, MD

- Developmental Therapeutics - Experimental Therapeutics

Michael L. Maitland, MD, PhD

- #3006-First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma.

Daniel Shao-Weng Tan, BSc, MBBS

- #3007-Dual inhibition of IGFR and mTOR pathways.

Aung Naing, MD, FACP

- #3008-A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotuzumab (DALO) in patients (pts) with advanced solid tumors.

Serena Di Cosimo

- #3009-First-in-class phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity.

Timothy Anthony Yap

- Discussion: Drugging the IGF1R/Akt/mTOR signaling network

Manuel Hidalgo, MD, PhD

- #3010-Phase I study of the investigational drug MLN8237, an Aurora A kinase (AAK) inhibitor, in patients (pts) with solid tumors.

Elizabeth Claire Dees, MD

- #3011-A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors.

Klaus B. Moss

- #3012-Phase I, first-in-human study of the centromere-associated protein e (CENP-E) inhibitor GSK923295 in patients with advanced solid tumors (Study CPE107602).

Kyle D. Holen

- Discussion: Novel agents and targets in mitosis

Johann Sebastian De Bono, MD, PhD

- #3013-Phase I study of TRC105 (anti-CD105 [endoglin] antibody) therapy in patients with advanced refractory cancer.

David S. Mendelson

- #3014-A first-in-human phase I study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously every three weeks in patients with advanced solid tumors.

Colin D. Weekes, MD, PhD

Session Title: #228: PARP Inhibition: DNA Repair as the Target

Session Type: Clinical Science Symposium

Date: Saturday, June 5

Location: E Arie Crown Theater

Time: 4:30 PM - 6:00 PM

- PARP Inhibition: DNA Repair as the Target

Patrick Johnston, MD, PhD

- PARP Inhibition: DNA Repair as the Target

Eunice Lee Kwak, MD, PhD

- Discussion: PARP as a Therapeutic Target

Alan Hilary Calvert, MD

- #3000-Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with cyclophosphamide.

Antoinette R. Tan, MD, MSc

- #3001-First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers.

Shahneen K. Sandhu

- #3002-Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.

Karen A. Gelmon, MD, FRCPC

- Discussion: State of Development for PARP inhibition

James H. Doroshow, MD

Session Title: #167: Highlights of the Day I including Clinical Trials Participation Awards

Session Type: Highlights of the Day

Date: Sunday, June 6

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day I including Clinical Trials Participation Awards

Everett E. Vokes, MD

- Clinical Trials Participation Awards

Douglas W. Blayney, MD

- Discussion: Lymphoma and Plasma Cell Disorders

Bruce D. Cheson, MD

- Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy

Alan B Sandler, MD

- Discussion: Patient and Survivor Care

Gretchen Genevieve Kimmick, MD

- Discussion: Melanoma/Skin Cancers

F. Stephen Hodi, MD

Session Title: #218: The MEK Pathway

Session Type: Clinical Science Symposium

Date: Sunday, June 6

Location: E354a

Time: 8:00 AM - 9:30 AM

- The MEK Pathway

Alex A. Adjei, MD, PhD

- Discussion: Introduction

David B. Solit, MD

- #2503-Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.

Jeffrey R. Infante

- #2504-First-in-human phase I; safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors.

Jean-Pierre Delord

- #2505-Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors.

Mitesh J. Borad

- Discussion: Closing

Patricia LoRusso, DO

Session Title: #217: Smoothened/Hedgehog/Gamma Secretase

Session Type: Clinical Science Symposium

Date: Sunday, June 6

Location: E353

Time: 9:45 AM - 11:15 AM

- Smoothened/Hedgehog/Gamma Secretase

S. Gail Eckhardt, MD

- Discussion: Introduction

Patricia LoRusso, DO

- #2500-A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors.

Jordi Rodon Ahnert

- #2501-A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors.

Lillian L. Siu, MD, FRCPC

- #2502-A phase I study of RO4929097, a novel gamma secretase inhibitor, in patients with advanced solid tumors.

Anthony W Tolcher

- Discussion: Closing Remarks

Charles M. Rudin, MD, PhD

Session Title: #44: Evaluating the Evidence and Marketing of Pharmacogenomic Tests

Session Type: Education Session

Date: Sunday, June 6

Location: E353

Time: 11:30 AM - 12:45 PM

- Overview of pharmacogenomics: history, development and role in FDA labeling

Howard L. McLeod, PharmD

- Cyp2D6 testing and tamoxifen

Matthew P. Goetz, MD

- Clinical cases in pharmacogenomics

Michael L. Maitland, MD, PhD

Session Title: #143: Plenary Session including Science of Oncology Award and Lecture

Session Type: Plenary Session

Date: Sunday, June 6

Location: N Hall B1

Time: 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture

Douglas W. Blayney, MD

- Plenary Session including Science of Oncology Award and Lecture

Daniel F. Hayes, MD

- Plenary Session including Science of Oncology Award and Lecture

Frank McCormick, PhD, FRS

- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

Robert A Burger

- Discussion

Elizabeth A. Eisenhauer, MD

- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).

- Discussion

Martin J. Edelman, MD

- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

Steven O'Day, MD

- Discussion: Ipilimumab: The light at the end of the tunnel?

Vernon K Sondak, MD

Session Title: #176: Developmental Therapeutics - Experimental Therapeutics

Session Type: Poster Discussion Session

Date: Sunday, June 6

Location: E450b

Time: 2:00 PM - 6:00 PM

- Developmental Therapeutics - Experimental Therapeutics

Ross A. Soo, MD

- Developmental Therapeutics - Experimental Therapeutics

Patrick Schoffski, MD, MPH

1 #3015-A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors.

Roger B Cohen

2 #3016-Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.

Valentine M Macaulay

3 #3017-A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).

Heather A. Wakelee, MD

4 #3018-Safety and pharmacokinetics (PK) of AMG 479 in combination with erlotinib (E) or sorafenib (S) in patients (pts) with advanced solid tumors.

Igor Puzanov

- Discussion: Interrupting Growth Factor Pathways Cross-Talk: Combinations With Erlotinib

Tomislav Dragovich, MD, PhD

5 #3019-Association of the *hemochromatosis (HFE)* gene with pazopanib-induced transaminase elevations in renal cell carcinoma.

Chun-Fang Xu

6 #3020-Effect of coadministration of statins on neutropenia in a phase I genotype-directed dose-escalation study of irinotecan.

Federico Innocenti

7 #3021-Inherited genetic variation in *EPHA5*, *FGD4*, and *NRDG1* and paclitaxel (P)-induced peripheral neuropathy (PN): Results from a genome-wide association study (GWAS) in CALGB 40101.

Deanna L. Kroetz

8 #3022-Systemic delivery of siRNA via targeted nanoparticles in patients with cancer: Results from a first-in-class phase I clinical trial.

Antoni Ribas, MD

9 #3023-Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors.

Patricia Tresca

10 #3024-A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors.

Alex A. Adjei, MD, PhD

11 #3025-Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer.

Robert C. Newton

12 #3026-Phase (P) I study of PF-00299804 (PF) combined with figitumumab (FI; CP-751,871) in patients (pts) with advanced solid tumors (ASTs).

Emiliano Calvo

13 #3027-A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors.

Giuseppe Giaccone

- Discussion: Design of early development combination trials

Elizabeth A. Eisenhauer, MD

14 #3028-Final report of phase I clinical, pharmacokinetic (PK), pharmacodynamic (PD) study of PF-00562271 targeting focal adhesion kinase (FAK) in patients (pts) with solid tumors.

Neesha C. Dhani

15 #3029-Utilizing mechanistic PK/PD modeling to simultaneously examine free CCL2, total CCL2, and CNTO 888 serum concentration time data.

Gerald J. Fetterly

16 #3030-A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies.

Irene Brana

17 #3031-Pharmacokinetic (PK) and pharmacodynamic (PD) results from two phase I studies of the investigational selective Aurora A kinase (AAK) inhibitor MLN8237: Exposure-dependent AAK inhibition in human tumors.

Andres Cervantes-Ruiperez

18 #3032-Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies.

Richard R. Furman

19 #3033-Pharmacodynamically guided dose selection of PF-00337210, a VEGFR2 tyrosine kinase (TK) inhibitor, in a phase I study.

Glenn Liu

- Discussion: Applying PK/PD principles to development of anticancer agents.

Jan H. M. Schellens, MD, PhD

Session Title: #80: New Technology in Cancer Immune Therapy

Session Type: Education Session

Date: Sunday, June 6

Location: E353

Time: 4:45 PM - 6:00 PM

- T cell engineering for adoptive immunotherapy

Zelig Eshhar, PhD

- Chimeric Immunoreceptor Engineered T-cells

Michel Sadelain, MD, PhD

- Combinatorial immunotherapy

Leisha A. Emens, MD, PhD

Session Title: #243: Developmental Therapeutics - Experimental Therapeutics

Session Type: Poster Discussion Session

Date: Sunday, June 6

Location: E Hall D2

Time: 5:00 PM - 6:00 PM

- Developmental Therapeutics - Experimental Therapeutics

Ross A. Soo, MD

- Developmental Therapeutics - Experimental Therapeutics

Patrick Schoffski, MD, MPH

1 #3015-A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors.

Roger B Cohen

2 #3016-Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.

Valentine M Macaulay

3 #3017-A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).

Heather A. Wakelee, MD

4 #3018-Safety and pharmacokinetics (PK) of AMG 479 in combination with erlotinib (E) or sorafenib (S) in patients (pts) with advanced solid tumors.

Igor Puzanov

- Discussion: Interrupting Growth Factor Pathways Cross-Talk: Combinations With Erlotinib

Tomislav Dragovich, MD, PhD

5 #3019-Association of the *hemochromatosis (HFE)* gene with pazopanib-induced transaminase elevations in renal cell carcinoma.

Chun-Fang Xu

6 #3020-Effect of coadministration of statins on neutropenia in a phase I genotype-directed dose-escalation study of irinotecan.

Federico Innocenti

7 #3021-Inherited genetic variation in *EPHA5*, *FGD4*, and *NRDG1* and paclitaxel (P)-induced peripheral neuropathy (PN): Results from a genome-wide association study (GWAS) in CALGB 40101.

Deanna L. Kroetz

8 #3022 Systemic delivery of siRNA via targeted nanoparticles in patients

9 #3023-Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors.

Patricia Tresca

10 #3024-A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors.

Alex A. Adjei, MD, PhD

11 #3025-Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer.

Robert C. Newton

12 #3026-Phase (P) I study of PF-00299804 (PF) combined with figitumumab (FI; CP-751,871) in patients (pts) with advanced solid tumors (ASTs).

Emiliano Calvo

13 #3027-A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors.

Giuseppe Giaccone

- Discussion: Design of early development combination trials

Elizabeth A. Eisenhauer, MD

14 #3028-Final report of phase I clinical, pharmacokinetic (PK), pharmacodynamic (PD) study of PF-00562271 targeting focal adhesion kinase (FAK) in patients (pts) with solid tumors.

Neesha C. Dhani

15 #3029-Utilizing mechanistic PK/PD modeling to simultaneously examine free CCL2, total CCL2, and CNTO 888 serum concentration time data.

Gerald J. Fetterly

16 #3030-A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies.

Irene Brana

17 #3031-Pharmacokinetic (PK) and pharmacodynamic (PD) results from two phase I studies of the investigational selective Aurora A kinase (AAK) inhibitor MLN8237: Exposure-dependent AAK inhibition in human tumors.

Andres Cervantes-Ruiperez

18 #3032-Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110 δ isoform, in patients with relapsed or refractory hematologic malignancies.

Richard R. Furman

19 #3033-Pharmacodynamically guided dose selection of PF-00337210, a VEGFR2 tyrosine kinase (TK) inhibitor, in a phase I study.

Glenn Liu

- Discussion: Applying PK/PD principles to development of anticancer agents.

Jan H. M. Schellens, MD, PhD

Session Title: #168: Highlights of the Day II including Partners in Progress Award

Session Type: Highlights of the Day

Date: Monday, June 7

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award

Kim Allyson Margolin, MD

- Highlights of the Day II including Partners in Progress Award

Douglas W. Blayney, MD

- Partners in Progress Award Recipient

Ellen V. Sigal, PhD

- Discussion: Genitourinary (Prostate) Cancer

Nicholas J. Vogelzang, MD

- Discussion: Gastrointestinal (Colorectal) Cancer

Howard S. Hochster, MD

- Discussion: Gynecologic Cancer

Claire F. Verschraegen, MD

- Discussion: Myeloma

Jean L. Harousseau, MD

- Discussion: Cancer Prevention/Epidemiology

Scott Michael Lippman, MD

Session Title: #197: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

Session Type: General Poster Session

Date: Monday, June 7

Location: S Hall A2

Time: 8:00 AM - 12:00 PM

1A #2539-A phase I study of CD40 agonist monoclonal antibody (CP-870, 893) with gemcitabine in pancreatic cancer.

Gregory Lawrence Beatty

1B #2540-Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors.

David S. Hong, MD

1C #2541-A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors.

Daniel D. Von Hoff, MD

1D #2542-Assessment of circulating tumor cell (CTC) patterns among disease-free breast cancer patients vaccinated with adjuvant HER2/neu-based peptide vaccines.

Kevin S. Clive

1E #2543-PET imaging of [11C]docetaxel uptake and tumor perfusion in lung cancer.

Astrid A. van der Veldt

1F #2544-Effect of a novel recombinant alphaviral vector on tolerance to self-antigen in the setting of elevated regulatory T cells.

Michael Morse

1G #2545-Phase I study of vorinostat for patients with advanced solid tumors and hepatic dysfunction: An NCI organ dysfunction working group (ODWG) study (NCI #8057).

Merrill J. Egorin, MD

1H #2546-A phase I/II study of intravenous Regin-G and Regin-C for cancer immunotherapy: The GeneVieve protocol.

Jorge G. Ignacio

2A #2547-Phase I trial of BMS-690514 in combination with paclitaxel/carboplatin (PC) in patients with advanced or metastatic solid tumors.

Laura Quan Man Chow, MD, FRCPC

2B #2548-Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CXCL2) in patients (nts) with advanced solid tumors.

2C #2549-New approach for assessment of potential ethnic differences in parallel phase I/II studies in the United States and Asia.

Toshihiko Doi

2D #2550-Overall survival (OS) analysis of a phase I trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Ravi Amrit Madan

2E #2551-The trifunctional antibody catumaxomab: Correlation between immunological response and clinical outcome—New analysis of a pivotal phase II/III study.

Marion Gabriele Ott

2F #2552-A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of CHR-3996, a class 1 selective histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors.

Udai Banerji

2G #2553-Pharmacokinetics (PK) of PF-562271, a focal adhesion kinase (FAK) inhibitor, and its effect on CYP3A in patients with advanced nonhematologic malignancies.

Huiping Xu

2H #2554-Final results of a phase Ib trial of PR104, a pre-prodrug of the bioreductive prodrug PR104A, in combination with gemcitabine (G) or docetaxel (D) in patients with advanced solid tumors.

Michael B. Jameson

3A #2555-CTLA-4 blockade with ipilimumab increases peripheral CD8+ T cells: Correlation with clinical outcomes.

Arvin Yang, MD, PhD

3B #2556-ANG1005: Results of a phase I study in patients with advanced solid tumors and brain metastases.

John Sarantopoulos

3C #2557-Phase I and pharmacokinetic study of everolimus and capecitabine in patients with solid tumors.

Johanna Wilmink

3D #2558-A phase I, open-label mass balance study of the hedgehog pathway inhibitor (HPI) GDC-0449 in healthy female subjects of non-childbearing potential.

Bert L. Lum, PharmD

3E #2559-NCCAM/NCI phase I study of mistletoe extract and gemcitabine in patients with advanced solid tumors.

Patrick J. Mansky, MD

3F #2560-A phase I study of sonopozumab (S), a humanized monoclonal antibody to sphingosine-1-phosphate (S1P), in patients with advanced solid tumors.

Michael S. Gordon

3G #2561-Phase I accelerated dose-escalating safety and pharmacokinetic (PK) study of aryl-hydrocarbon receptor-mediated aminoflavone prodrug AFP464 in advanced solid tumors.

Christophe Massard

3H #2562-A phase I safety and tolerability study of vorinostat (V) in combination with sorafenib (S) in patients with advanced solid tumors, with exploration of two tumor-type specific expanded cohorts at the recommended phase II dose (renal and non-small cell lung carcinoma).

A. Dasari

4A #2563-A phase I study of bortezomib (BTZ) and temozolomide (TMZ) in patients with advanced solid tumors.

Jana Portnow

4B #2564-Nano-immunoassay profiling of ERK and MEK isoforms in fine-needle aspirates of solid tumors.

Alice C. Fan

4C #2565-Effect of a novel II-key hybrid HER2/neu peptide (AE37) vaccine with GM-CSF as compared to GM-CSF alone on levels of regulatory T-cell (Treg) populations.

Guy T. Clifton

4D #2566-Pharmacology of high-dose methotrexate in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG #20 trial.

Andres J. Ferreri

4E #2567-Effect of TGF- β 1 expressed on tumor-derived exosomes on survival and function of regulatory T cells.

Hideya Onishi, DrPH, MD

4F #2568-Factors of interindividual hematopoietic toxicity of carboplatin.

Etienne Chatelut

4G #2569-Effect of prophylactic administration of recombinant human thrombopoietin on chemotherapy-induced severe thrombocytopenia in patients with advanced non-small cell lung cancer: A prospective self-control clinic study.

Shun Lu

4H #2570-A phase I study of ARRY-520 in solid tumors.

Priscila H. B. Goncalves

5A #2571-A phase I and pharmacokinetic single agent study of pazopanib (P) in patients (Pts) with advanced malignancies and varying degrees of liver dysfunction (LD).

Stephen Shibata

5B #2572-Phase I, pharmacokinetic study of temsirolimus in combination with nelfinavir in patients with solid tumors.

Wiete Kromdijk

5C #2573-Phase I safety and pharmacology study of the EpCAM/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric, or lung cancer.

Walter M. Fiedler

5D #2574-Clinical outcome of first-line melanoma patients who continue tremelimumab in spite of early disease progression.

Diane I. Healey

5E #2575-Early disease progression in a phase I study of bortezomib (B), cetuximab (C), and intensity-modulated radiation therapy (IMRT) for squamous cell carcinoma of the head and neck (SCCHN).

Carter Van Waes

5F #2576-Final results from a phase I study of oral TRC102 (methoxyamine HCl), an inhibitor of base-excision repair, to potentiate the activity of pemetrexed in patients with refractory cancer.

Glen J. Weiss

5G #2577-Genetic polymorphisms of metabolizing enzymes and transporters correlate with pharmacokinetics (PK) and pharmacodynamics (PD) of amrubicin.

Yoshinori Makino

5H #2578-Identification of novel prostate cancer-associated antigens through antibody profiling of prostate cancer patients treated with CTLA-4 blockade.

Lawrence Fong

6A #2579-Clinical and immunological responses to a DNA fusion vaccine in patients with carcinoembryonic antigen-expressing tumors: A Cancer Research UK phase I/II study.

Christian H.H Ottensmeier

6B #2580-Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors.

S. Gail Eckhardt, MD

6C #2581-Histopathologic and immunohistochemical findings of skin rash to HER1 and HER1/2 inhibitors during anticancer therapy.

Beatrice Nardone

6D #2582-Eribulin mesylate pharmacokinetics in patients with hepatic impairment.

Petronella Witteveen

6E #2583-PIK3CA, KRAS, and BRAF mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.

Filip Janku

6F #2584-Pharmacokinetics (PK) of oxaliplatin (OX) after intraperitoneal (IP) and intravenous (IV) administration in patients with gynecological malignancies.

Austin J. Combest

6G #2585-Phase I pharmacokinetics and metabolic pathway of belinostat in patients with hepatocellular carcinoma.

Ling-Zhi Wang

6H #2586-Impact of antidiabetic agents on the survival of subjects with colorectal cancer (CRC).

Thandiwe C. Gray

7A #2587-Correlation of immune responses with survival in a randomized phase II study investigating multi-peptide vaccination with IMA901 plus or minus low-dose cyclophosphamide in advanced renal cell carcinoma (RCC).

Harpreet Singh

7B #2588-Improving patient selection for oncology phase Ι trials: Predictors of 90-day mortality and overall survival.

Nicole Grace Chau, MD, FRCPC

7C #2589-Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors.

Umang Swami, MBBS

7D #2590-Phase I/II study of BIBW 2992 with or without daily temozolomide in the treatment of patients with recurrent malignant glioma.

David A. Reardon

7E #2591-A phase I study of sirolimus (rapamycin) and bevacizumab in patients with advanced malignancies.

Ezra E. W. Cohen, MD, FRCPC

7F #2592-A phase II, single-arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with advanced non-small cell lung cancer (NSCLC).

Aradeep Chatterjee, MD

7G #2593-Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: Response, survival, and prognostic factors.

Marine Gilabert

7H #2594-Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors.

Martin Zweifel

8A #2595-Phase I trial of sequential azacitidine and valproic acid plus carboplatin in the treatment of patients with advanced malignancies.

Ernesto Bustinza-Linares

8B #2596-Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients.

Weiwei Tan

8C #2597-Hyperglycemia, hypertriglyceridemia, and hypercholesterolemia in a phase I trial of the combination of an mTOR inhibitor and IGF-1 receptor inhibitor.

Naifa Busaidy

8D #2598-Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC).

Mark Kozloff

8E #2599-A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.

Lulama Rhoda Molife

8F #2600-Evaluation of poxviruses targeting the tumor microenvironment for cancer therapy.

Dae Won Kim

8G #2601-A comparison of the Cockcroft-Gault (CG) and the modification of diet in renal disease (MDRD) equations for estimating renal function and guiding dose adjustment of oncology-related drugs.

Joseph A. Grillo, PharmD

8H #2602-A phase I study of prolonged infusion of triapine in combination with a fixed-dose rate of gemcitabine in patients with advanced solid tumors.

Amir Mortazavi

9A #2603-Phase I study of proteasome inhibitor bortezomib (B) concurrent with re-irradiation therapy (re-RT) for recurrent squamous cell carcinoma of the head and neck (SCCHN).

John Charles Morris

9B #2604-Toxicity in 1,181 patients with advanced solid tumors treated in phase I clinical trials of predominantly targeted agents: The M. D. Anderson Cancer Center experience.

Jennifer J. Wheeler

9C #2605-A phase I study of ABT-888 (A) in combination with metronomic cyclophosphamide (C) in adults with refractory solid tumors and lymphomas.

Shivaani Kummar

9D #2606-Single-nucleotide polymorphisms (SNPs) of CYP19A1 and plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment.

Gianluigi Lunardi

9E #2607-Phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493): First-in-human clinical experience of a folate receptor-targeted chemotherapeutic agent administered on days 1, 4, 8, and 11 of a 21-day cycle.

Maja De Jonge

9F #2608-Bystander vaccine therapy in mantle cell lymphoma (MCL): Phase II clinical results.

Bijal Dinesh Shah

9G #2609-Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma.

Margaret A. Marshall

9H #2610-Phase I trial of dasatinib (D) and lapatinib (L).

Charles Erlichman

10A #2611-Trabectedin (AP 12009) in the treatment of patients with advanced tumors: Completion of dose-escalation and first efficacy data.

Helmut Oettle

10B #2612-Phase I, dose-escalation study of BIIB022 (anti-IGF-1R antibody) in advanced solid tumors.

Margaret von Mehren, MD

10C #2613-A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941.

Richard D. Baird, MBBS, MRCP

Session Title: #198: Developmental Therapeutics - Experimental Therapeutics

Session Type: General Poster Session

Date: Monday, June 7

Location: S Hall A2

Time: 8:00 AM - 12:00 PM

10D #3034-Phase I study of PF-03446962, a fully human mab against ALK 1, a TGF β ; receptor involved in tumor angiogenesis.

Laura Williams Goff

10E #3035-Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors.

Toshio Shimizu

10F #3036-French, multicentric, prospective study of dynamic contrast-enhanced ultrasound (DCE-US) for the evaluation of antiangiogenic treatments in 400 patients.

Nathalie Lassau

10G #3037[^]-Placental growth factor as a marker of therapeutic response to treatment with motesanib in patients with progressive advanced thyroid cancer, advanced nonsquamous non-small cell lung cancer, and locally recurrent or advanced metastatic breast cancer.

Michael B. Bass

10H #3038-Final results from a phase I study of TRC093 (humanized anti-cleaved collagen antibody) in patients with solid cancer.

Francisco Robert

11A #3039-Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV).

Herbert Hurwitz

11B #3040-Treatment of VHL patients with sunitinib: Clinical outcomes and translational studies.

Surena F. Matin

11F #3041-Phase Ib study of PTC299, a novel oral inhibitor of tumor VEGF expression, in patients with advanced cancer.

Gary K. Schwartz, MD

11G #3042-Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.

Jared Gollob

11H #3043-Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P) in patients (pts) with refractory solid tumors.

12B #3045-Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.

Marlies HG Langenberg

12F #3046-A phase I study of sunitinib malate (S) and gemcitabine (G) in solid tumors.

Smitha S. Krishnamurthi

12G #3047-Phase I clinical and pharmacological study of multiple schedules of pazopanib (P) and epirubicin (EPI) in patients with advanced solid tumors.

A. Fasolo

12H #3048-Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC).

Ben Suttle

13A #3049-Direct in vivo evaluation of tumor VEGFR in response to treatment with pazopanib: A novel molecular imaging study.

Susanta K. Sarkar

13B #3050-Concurrent assessment of vasculature and proliferative pharmacodynamics in patients treated with VEGFR TKI.

Robert Jeraj

13C #3051-Assessment of early vascular effects of the angiogenesis inhibitor sunitinib (SU) in renal cell carcinoma (RCC) by dynamic contrast enhanced MRI (DCE-MRI) and diffusion weight MRI (DWI) at 3 tesla (T).

Ingrid Desar

13D #3052-Predictive and mechanistic factors of tyrosine kinase inhibitor (TKI) induced macrocytosis.

Paul Hamberg

13E #3053-Extended linifanib therapy in patients with advanced solid tumors in a phase I trial.

Boon C. Goh

13F #3054-A first-in-human, phase I pharmacodynamic (PD) and pharmacokinetic (PK) study of BNC105P, a novel vascular disrupting agent (VDA) and inhibitor of cancer cell proliferation.

Geoffrey Chong

13G #3055-Phase II trial of dose-escalated sorafenib in advanced solid tumors.

Thomas John Semrad

13H #3056-Association of VEGF feedback production in bevacizumab therapy with systemic response.

Patrick Starlinger

14A #3057-A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results.

E. Angevin

14B #3058-A phase I dose-escalation study of IMGN388 in patients with solid tumors.

Dana Shelton Thompson

14C #3059-A phase I study of two different schedules of nab-paclitaxel (Nab-p) with ascending doses of vandetanib (V) in patients (pts) with advanced solid tumors.

Anthony B. El-Khoueiry, MD

14D #3060-Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer.

Dennis J. Slamon, MD, PhD

14E #3061-Final analysis of a phase I single dose escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors.

Thierry Gil

14F #3062-Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase.

Nicoletta Brega

14G #3063-Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in combination with gemcitabine in advanced solid tumors.

Rastislav Bahleda

14H #3064-A phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors.

Adil Daud

15A #3065-Phase I study of the oral CDK-TRKA inhibitor PHA-848125 administered with prolonged schedules of administration.

Sara Cresta

15B #3066-Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors.

Peter J. Rosen

15C #3067-A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

Suzanne Leijen

15D #3068-Safety and clinical activity of the histone deacetylase inhibitor givinostat in combination with meclorothamine in relapsed/refractory Hodgkin lymphoma (HL).

Carmelo Carlo-Stella

15E #3069-Phase I pharmacokinetic and pharmacodynamic study of the heat shock protein 90 inhibitor AT13387 in patients with refractory solid tumors.

Geoffrey Shapiro

15F #3070-A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors.

Cristian Moldovan

15G #3071-First-in-human, phase I dose-escalation study of investigational drug MLN9708, a second-generation proteasome inhibitor, in advanced nonhematologic malignancies.

Eve T. Rodler

15H #3072-Phase I dose-finding study of BN80927 as an intravenous infusion every 21 days in patients with advanced malignant solid tumors.

Thierry Lesimple

16A #3073-Emergence of oral targeted agents in early clinical development: Experience at M. D. Anderson Cancer Center (MDACC) Clinical and Translational Research Center (CTRC).

Kirk Salvatore Culotta

16B #3074-Application of multinomial (MN) phase II designs in trials of targeted agents.

Rahima Jamal

16C #3075-Novel strategy to identify drugs that delay relapse.

Marcia Hall

16D #3076-Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1 α ;

Raoul Tibes

16E #3077-Phase I trial of OGX-427, a 2'-methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): Final results.

Sebastien J. Hotte

16F #3078-A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.

Anne M. Traynor, MD

16G #3079-A first-in-human, phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma.

Saoirse Dolly

16H #3080-A phase I/II study of oncolytic reovirus plus carboplatin/paclitaxel in patients with advanced solid cancers with emphasis on squamous cell carcinoma of the head and neck (SCCHN).

Eleni M Karapanagiotou

17A #3081-Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study.

Suzanne Fields Jones

17B #3082-A phase I study of EC0225 administered weeks 1 and 2 of a 4-week cycle.

Sunil Sharma

17C #3083-A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered twice weekly in patients with solid tumors.

James M. Cleary

17D #3084-Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: A phase I/II, open-label study.

Robert Dreicer, MD

17E #3085-A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma.

Phioanh Leia Nghiemphu

17F #3086-Pharmacokinetic analysis and pharmacodynamic evidence of autophagy inhibition in patients with newly diagnosed glioblastoma treated on a phase I trial of hydroxychloroquine in combination with adjuvant temozolomide and radiation (ABTC 0603).

Myrna Rachel Rosenfeld, MD, PhD

17G #3087-First-in-human study evaluating safety and pharmacokinetics of endoxifen, a potent estrogen-receptor antagonist for breast cancer.

Ateeq Ahmad

17H #3088-A phase I study of the folate-targeted conjugate EC0489 in patients with refractory or advanced metastatic cancer.

Wael A. Harb

18A #3089-Final results from a phase I, dose escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase.

Antonio Jimeno

18B #3090-Temsirolimus (TEM) in endometrial cancer: Predictors of response and progression.

Rachel Anne Goodwin

18C #3091-Fasting glucose and triglycerides as biomarkers of mTOR inhibition, evidence of a categorical response.

Anitha S Nallari

18D #3092-Gene expression analysis in human hair bulbs as a potential pharmacodynamic readout in the LDE225 clinical program.

Kristine Rose

18E #3093-Sensitive detection of gamma-H2AX induction as a pharmacodynamic marker for profiling patients with cancer treated with topotecan.

Darren O. Davis

18F #3094-Characterization of proliferative rebound during drug holiday by FLT-PET imaging in patients treated with sunitinib (SU).

Michael Roger Harrison

18G #3095-Characterization of brivanib pharmacokinetics and exposure-response (E-R): Relationship of fatigue in patients with advanced and metastatic solid tumors.

Xiaoning Wang

18H #3096-Pharmacokinetic, pharmacodynamic, and phase II study of gefitinib in patients with malignant pleural effusion from non-small cell lung cancer.

Akihito Kubo

19A #3097-Association of vorinostat with decrease in gene expression of proliferation-related genes in tumors from women with newly diagnosed breast cancer.

Vered Stearns, MD

19B #3098-Pharmacogenetic factors predicting the need for a higher dose of imatinib.

Heinz-Josef Klumpen

19C #3099-DPYD single nucleotide polymorphisms (SNPs) and haplotypes in patients (pts) with metastatic colorectal cancer and toxicity of capecitabine.

Maarten J. Deenen, PharmD

19D #3100-Relationship of *HLA-DQA1*0201* and lapatinib-induced hepatotoxicity in women with advanced breast cancer.

Colin F Spraggs

19E #3101-The contribution of *UGT1A* and *ABCB1* to irinotecan-induced toxicity: A prospective pharmacogenetic study of patients with metastatic colorectal cancer.

Eric Levesque

19F #3102-Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors.

Sant P. Chawla

19G #3103-Phase I study of AV-412, a novel, irreversible EGFR inhibitor, administered intermittently in patients with advanced solid tumors.

Karen Kelly

19H #3104-Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors.

Jayesh Desai

20A #3105-A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma.

David C. Smith

20B #3106-Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase I study (Study 265-101).

Michel A. Drouin

20C #3107-Evaluation of serum protein mass spectrometry technology to identify NSCLC patients with tumor response to gefitinib.

Yi Pei

20D #3108-A phase I study of oral administration of MGCD265 in patients with advanced malignancies (Study 265-102).

Elisabeth I. Heath

Session Title: #221: Paths for Clinical Development of PI3K Inhibition

Session Type: Clinical Science Symposium

Date: Monday, June 7

Location: E Arie Crown Theater

Time: 8:00 AM - 9:30 AM

- Paths for Clinical Development of PI3K Inhibition

A. Dimitrios Colevas, MD

- Paths for Clinical Development of PI3K Inhibition

Pasi A. Janne, MD, PhD

- Discussion

Neal Rosen, MD, PhD

- #3003-A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors.

Jose Baselga, MD

- #3004-A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies.

Gerald Edelman

- #3005-First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.

Howard Burris

- Discussion: Next steps in clinical development of PI3K inhibitors?

Carlos L. Arteaga, MD

Session Title: #113: Clinical Research Mentorships: How to Find a Mentor, How to Be a Mentor

Session Type: Meet the Professor Session

Date: Monday, June 7

Location: E451b

Time: 9:45 AM - 11:00 AM

- Clinical Research Mentorships: How to Find a Mentor, How to Be a Mentor

Evanthia Galanis, MD

Session Title: #14: Are We Asking Too Much? The Challenges of Mandatory Research Biopsies within Clinical Trials

Session Type: Education Session

Date: Monday, June 7

Location: S100b

Time: 11:30 AM - 12:45 PM

- WHAT CAN WE LEARN?: The scientific justification for consideration of mandatory research biopsy within some clinical trials. What questions can research biopsies address? Are they safe? What have we learned from such studies? What is at stake if make all correlative science components optional?

Eric P. Winer, MD

- ARE WE ASKING TOO MUCH?: Ethical Concerns over Mandatory Research Biopsy: Concerns over coercion. Need to separate therapeutic trials from correlative studies. Perspectives of a Patient Advocate within a National Cancer Institute Cooperative Group.

Michael Katz

- THE ETHICAL FRAMEWORK: Can we pursue mandatory research biopsy under select circumstances? Ethical arguments for mandatory research biopsy, ways to promote protection of research subjects and pursue important research. A proposed framework for consideration of mandatory research biopsy and clarification of the assumptions underlying different positions on this issue.

Jeffrey M. Peppercorn, MD, MPH

Session Title: #26: Combined Modalities in Pancreatic Cancer: Should Recent Trials Change Our Practice?

Session Type: Education Session

Date: Monday, June 7

Location: N Hall B1

Time: 1:15 PM - 2:30 PM

- The role of neoadjuvant vs adjuvant chemotherapy in pancreatic cancer; what does the data tell us?

Gauri R. Varadhachary, MD

- Role of radiation in locally advanced pancreatic cancer

Theodore Steven Lawrence, MD, PhD

- Surgical approach in resectable and borderline resectable pancreas cancer

David Linehan, MD

Session Title: #57: Immunoconjugates as Cancer Therapeutics

Session Type: Education Session

Date: Monday, June 7

Location: S100b

Time: 1:15 PM - 2:30 PM

- The history and evolution of immunoconjugate treatment as anti- cancer therapy

Andrew Antony Raubitschek, MD

- The present state of trials using immunoconjugates targeting solid tumors and new strategies emerging from the lab.

Raffit Hassan, MD

- The present state of trials using immunoconjugates targeting lymphoma and heme malignancies and new strategies emerging from the lab.

Paul A. Hamlin, MD

Session Title: #85: Oral Chemotherapy: A Hard Pill to Swallow

Session Type: Education Session

Date: Monday, June 7

Location: S406 (Vista Room)

Time: 4:45 PM - 6:00 PM

- General issues relevant to oral chemotherapy and patient health care literacy

Merrill J. Egorin, MD

- Drug-drug and food-drug interactions relevant to oral chemotherapy agents

Jan Hendrik Beumer, PhD, PharmD

- Adherence and persistence (or lack thereof) with oral agents. The scope of the problem. What the data say.

Ann H. Partridge, MD

Session Title: #169: Highlights of the Day III

Session Type: Highlights of the Day

Date: Tuesday, June 8

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day III

Kathy Miller, MD

- Discussion: Breast Cancer - Local/Regional and Adjuvant Therapy

Kathy Miller, MD

- Discussion: Lung Cancer - Metastatic

Charles M. Rudin, MD, PhD

- Discussion: Sarcoma

Gary K. Schwartz, MD

- Discussion: Gastrointestinal (Noncolorectal) Cancer

C. D. Blanke, MD

- Discussion: Head and Neck Cancer

Everett E. Vokes, MD

Session Title: #40: Developing Drugs in Special Populations: Organ Dysfunction Studies

Session Type: Education Session

Date: Tuesday, June 8

Location: E354b

Time: 8:00 AM - 9:15 AM

- Renal dysfunction studies

Daniel Mulkerin, MD

- Liver dysfunction studies

Ghassan K. Abou-Alfa, MD

- Regulatory considerations for organ dysfunction studies

Shiew-Mei Huang, PhD

Session Title: #92: Selection of Endpoints in Clinical Trials: From Bench to Trials to Practice

Session Type: Education Session

Date: Tuesday, June 8

Location: S100b

Time: 8:00 AM - 9:15 AM

- Use of molecular markers as surrogate endpoints in clinical trials

Carlos Cordon-Cardo, MD, PhD

- Design of Clinical Trials to Achieve Meaningful Results

Mary W Redman, PhD

- Translating Clinical Trial Results into Societal Benefit: The Role of Population-based Outcome Studies

Christopher M. Booth, MD

Session Title: #148: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

Session Type: Oral Abstract Session

Date: Tuesday, June 8

Location: E354a

Time: 9:30 AM - 12:30 PM

- Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

Tyler J. Curiel, MD

- #2506-Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.

Mario Sznol

- #2507-A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4.

Peter W. M. Johnson

- #2508-Phase I study of anti-CD25 mab daclizumab to deplete regulatory T cells prior to telomerase/survivin peptide vaccination in patients (pts) with metastatic breast cancer (MBC).

Andrew J. Rech, BS

- Discussion

Tyler J. Curiel, MD

- #2509-Cell therapy with EBV-specific cytotoxic T-lymphocytes for patients with nasopharyngeal carcinoma.

Patrizia Comoli

- #2510-Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematologic malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: A phase II study.

Shimon Slavin

- #2511-Vaccination with DC/RCC fusions following cytoreductive nephrectomy.

David Avigan

- #2512-A phase I study of bevacizumab in combination with sunitinib, sorafenib, erlotinib plus cetuximab, and trastuzumab plus lapatinib.

Gerald Steven Falchook

- #2513-First-line chemoimmunotherapy in metastatic breast carcinoma: Effect of a combination of paclitaxel and LAG-3 is (IMP321), a novel MHC

- #2514-Pharmacodynamic response in phase I combination study of ABT-888 and topotecan in adults with refractory solid tumors and lymphomas.

Jiuping Jay Ji, PhD

- Discussion

Mark J. Ratain, MD

Session Title: #45: Even Patients with Liver Dysfunction Can Get Chemotherapy!

Session Type: Education Session

Date: Tuesday, June 8

Location: E354b

Time: 9:45 AM - 11:00 AM

- Understanding assessment of liver function and viral hepatitis for the medical oncologist.

Lewis R. Roberts, PhD, MBChB

- Understanding the importance of hepatic function and dysfunction in metabolism of anticancer agents Delivering chemotherapy to the patient with liver dysfunction.

Timothy W. Synold, PharmD

- Management of dosing and side effects of specific chemotherapeutic agents.

Melanie B. Thomas, MD